Brett Villagrand, Genentech
S
Brett Villagrand
Associate Director, Strategy, BioOncology, Genentech
BORN: Australia; has lived in four countries
CAN'T LIVE WITHOUT: Rugby
On brand success:
Herceptin revolutionized the way to treat HER2-positive breast cancer. I've been fortunate enough to work on that brand for the last three years—and to be here at Genentech at the right time. We've been fairly successful, with sales at around $1.3 billion. It's been a roller coaster ride to get there because the brand's more than doubled its growth over the last four or five years. Now we're facing competition for the first time. But despite the entry of a new competitor, we've been able to keep them to less than 5 percent of the market. Far from resting, we've instead put a number of things in place that will help us maintain our leadership role in that area.
Brett Villagrand
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
